Innate Immunity to Adenovirus by Hendrickx, Rodinde et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Innate Immunity to Adenovirus
Hendrickx, Rodinde; Stichling, Nicole; Koelen, Jorien; Kuryk, Lukasz; Lipiec, Agnieszka; Greber, Urs F
Abstract: Human adenoviruses are the most widely used vectors in gene medicine, with applications
ranging from oncolytic therapies to vaccinations, but adenovirus vectors are not without side effects.
In addition, natural adenoviruses pose severe risks for immuno-compromised people, yet, infections are
usually mild and self-limiting in immuno-competent individuals. Here we describe how adenoviruses
are recognized by the host innate defense system during entry and replication in immune and non-
immune cells. Innate defense protects the host, and at the same time, represents a major barrier to
using adenoviruses as therapeutic interventions in humans. Innate response against adenoviruses involves
intrinsic factors present at constant levels, and innate factors induced by the host cell upon viral challenge.
These factors exert anti-viral effects by directly binding to viruses or viral components, or shield the virus,
for example soluble factors, such as blood clotting components, the complement system, preexisting
immunoglobulins or defensins. In addition, toll-like receptors and lectins in the plasma membrane and
endosomes are intrinsic factors against adenoviruses. Important innate factors restricting adenovirus in
the cytosol are tripartite motif-containing proteins (TRIM), nucleotide-binding oligomerization domain
(NOD)-like inflammatory receptors and DNA sensors triggering interferon, such as DEAD (Asp-Glu-
Ala-Asp) box polypeptide 41 (DDX41) and cyclic guanosine monophosphate-adenosine monophosphate
synthase (cGMP-AMP synthase, short cGAS). Adenovirus tunes the function of anti-viral autophagy,
and counters innate defense by virtue of its early proteins E1A, E1B, E3 and E4 and two virus-associated
noncoding RNAs VA-I and VA-II. We conclude by discussing strategies to engineer adenovirus vectors
with attenuated innate responses and enhanced delivery features.
DOI: 10.1089/hum.2014.001
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-93150
Accepted Version
Originally published at:
Hendrickx, Rodinde; Stichling, Nicole; Koelen, Jorien; Kuryk, Lukasz; Lipiec, Agnieszka; Greber, Urs F
(2014). Innate Immunity to Adenovirus. Human Gene Therapy, 25(4):265-284. DOI: 10.1089/hum.2014.001
 1 
Innate Immunity to Adenovirus 
 
Rodinde Hendrickx1*+, Nicole Stichling1*+, Jorien Koelen2, Lukasz Kuryk3, Agnieszka Lipiec4, Urs F. 
Greber1, 5 
 
1 Institute of Molecular Life Sciences, University of Zurich, Winterthurerstrasse 190, CH-
8057 Zurich, Switzerland;  
2 Department of Oncology, University of Oxford, Old Road Campus Research Building, 
Headington, UK-Oxford OX3 7DQ, UK;  
3 Oncos Therapeutics Ltd., Saukonpaadenranta 2, FI-00180 Helsinki, Finland;  
4 Batavia Bioservices, Bioscience Park, Zernikedreef 9, NL-2333 CK Leiden, The 
Netherlands;  
* Equal contribution;  
+ Molecular Life Sciences Graduate School, ETH and University of Zurich 
5 corresponding author 
 
Running head: 
Host innate response to adenovirus 
 
Key words: 
 
  
 2 
Abstract 
Human adenoviruses are the most widely used vectors in gene medicine, with 
applications ranging from oncolytic therapies to vaccinations, but adenovirus vectors are 
not without side effects.  In addition, natural adenoviruses pose severe risks for immuno-
compromised people, yet, infections are usually mild and self-limiting in immuno-
competent individuals.  Here we describe how adenoviruses are recognized by the host 
innate defense system during entry and replication in immune and non-immune cells.  
Innate defense protects the host, and at the same time, represents a major barrier to 
using adenoviruses as therapeutic interventions in humans.  Innate response against 
adenoviruses involves intrinsic factors present at constant levels, and innate factors 
induced by the host cell upon viral challenge.  These factors exert anti-viral effects by 
directly binding to viruses or viral components, or shield the virus, for example soluble 
factors, such as blood clotting components, the complement system, preexisting 
immunoglobulins or defensins.  In addition, toll-like receptors and lectins in the plasma 
membrane and endosomes are intrinsic factors against adenoviruses.  Important innate 
factors restricting adenovirus in the cytosol are tripartite motif-containing proteins (TRIM), 
nucleotide-binding oligomerization domain (NOD)-like inflammatory receptors and DNA 
sensors triggering interferon, such as DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 
(DDX41) and cyclic guanosine monophosphate-adenosine monophosphate synthase 
(cGMP-AMP synthase, short cGAS).  Adenovirus tunes the function of anti-viral 
autophagy, and counters innate defense by virtue of its early proteins E1A, E1B, E3 and 
E4 and two virus-associated noncoding RNAs VA-I and VA-II.  We conclude by 
discussing strategies to engineer adenovirus vectors with attenuated innate responses 
and enhanced delivery features.  
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Introduction 
Viruses are highly adapted to cues and machineries from the host, which ensures their 
propagation in a foreign environment, such as a eukaryotic cell.  Viruses are also 
professional gene delivery agents and capable of spreading from cell to cell and between 
individuals.  They can be harnessed for gene therapy to introduce customized genes to 
diseased cells (Kootstra and Verma 2003).  However, clinical gene therapy is not a 
simple task, as there are many biological and technical obstacles.   
A major bottleneck in molecular therapy is a shortage of efficient and nontoxic delivery 
agents.  Human adenoviruses (HAdVs) are the most widely used agents in gene therapy, 
largely due to their high efficiency in gene transfer and deep knowledge of their infection 
biology (http://www.abedia.com/wiley/vectors.php). Their well known ability to activate 
inflammatory responses makes them interesting candidates for vaccination trials. 
One of the major biological obstacles in gene therapy is that host cells contain intricate 
viral detection mechanisms that activate inflammatory or cytotoxic responses directed 
against viruses.  This innate immunity is based on a large variety of well studied inducible 
factors, such as proteins, lipids or RNA (for reviews, see Pichlmair and Reis E Sousa 
2007; Schoggins and Randall 2013).  More recently, it was shown that mammalian cells 
(besides plant and insect cells) have anti-viral RNA interference (Maillard et al., 2013).  
Mammalian cells accumulate small 22-nucleotide RNAs from viral replication 
intermediates and guide them to the argonaute proteins to eliminate viral RNA.  
Collectively, innate immunity steers the organism to adaptive immunity, which is 
pathogen specific, and comprises selective antibodies.  Both innate and adaptive 
immunity generally antagonize viral efficacy in gene therapy (reviewed in Janeway and 
Medzhitov 2002; Fejer et al., 2011; Russell et al., 2012), although the treatment of 
aggressive forms of cancer by therapeutic viruses can be enhanced by the inflammatory 
host response (for reviews, see Wong et al., 2010; Russell et al., 2012).  Here we 
summarize the current knowledge of the mechanisms that lead to inflammation and 
innate immunity in cells inoculated with HAdV.  
 
Early signaling – mobilizing cell defense 
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The outcome of virus-cell interactions ranges from productive or persistent infection to no 
infection where the virus is completely rejected.  Permissive cells support virus replication 
and produce progeny viruses, as their defense is out-powered by the virus.  In many 
instances, productive infections are cytolytic, and in the case of cancer cells oncolytic, 
and the cells die.  If cellular defense out-powers the virus, cells are non-permissive and 
do not produce infectious progeny virus.  Such infections are abortive.  If a set of viral 
genes is incompletely transcribed or translated, the infection is restrictive.  This can lead 
to persistent or in certain cases transforming infections, where viral DNA is maintained 
but progeny virus usually not produced or if so, at low levels.   
Infection can be tuned by signaling during entry and this can impact cell death by 
apoptosis, necrosis or pyroptosis, as well as innate signaling with pro- or anti-viral effects 
(Greber 2002; Faure and Rabourdin-Combe 2011; Mercer and Greber 2013).  Cell death 
signals emerge from viral engagement of death receptors, signaling during uncoating and 
post-entry events (for some reviews, see Lamkanfi and Dixit 2010; Danthi 2011; Agol 
2012; Kaiser et al., 2013).  Innate immune responses comprise intrinsic mechanisms, 
which directly restrict viral replication and assembly, therefore leading to non-
permissiveness of the cell (Yan and Chen 2012).   
Extrinsic innate immunity impairs infection by indirect mechanisms, which involves 
signaling to elicit an anti-viral state.  Extrinsic modulators include Toll-like receptors 
(TLRs), C-type lectin receptors (CLRs), RIG-I like receptors (RLRs), NOD-like receptors 
(NLRs), cytosolic DNA sensors, and effector molecules.  Antiviral effects can occur for 
example through engagement of cell surface or endosomal pattern recognition receptors 
(PRR), such as mannose receptor, dendritic cell-specific ICAM grabbing non-integrin 
(DC-SIGN), or defensins disrupting bacterial membranes or binding to viral capsids (Buck 
2008; Sato et al., 2009).  PRRs trigger complex intracellular signaling cascades, type 1 
interferon (IFN) production, and eventually lead to an anti-viral state of the host cell.  The 
following sections discuss how host innate defense senses HAdV, and how this triggers 
innate immune responses.  
 
HAdV entry – a gain of function process for the virus 
Adenovirus 
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Adenoviruses are icosahedral, non-enveloped double stranded (ds) DNA viruses 
infecting both dividing and quiescent cells in a species-specific manner. HAdVs comprise 
more than 55 types, and are the most frequently used vector in human gene therapy 
(Smith et al., 2010b).  According to hemagglutination and genome sequences there are 
seven species, HAdV-A, B, C, D, E, F, G (Harrach et al., 2011).  They are part of the 
genus Mastadenovirus.  HAdVs are considered to be non-oncogenic in humans.  They 
maintain episomal genomes in the nucleus without integration into host DNA (Harui et al., 
1999).   HAdV infections in immuno-competent individuals typically cause respiratory or 
gastrointestinal symptoms and are self-limiting.  Infections can, however, be fatal in 
immuno-deficient hosts or newborns (Echavarria 2008).  Yet, to date there are no 
effective drugs for the treatment of HAdV infections.  Even the well-established 
nucleoside inhibitor cidofovir has low clinical efficacy (Lenaerts and Naesens 2006; 
Skevaki et al., 2011; Greber et al., 2013).   
HAdVs are highly stable outside of cells, which is a great advantage for gene therapy 
(see Fig. 1A).  The crystal structure and high resolution cryo-EM structures for HAdV-C 
are available, providing a solid basis for rational engineering (Liu et al., 2010; Reddy et 
al., 2010).  Despite their great thermal and chemical stability (Buckland and Tyrrell 1963; 
Tuladhar et al., 2012), HAdV-C2/5 have evolved remarkably high efficacies for cell entry 
and uncoating of their DNA (for reviews, see Greber et al., 1994; Greber and Way 2006; 
Puntener and Greber 2009; Suomalainen and Greber 2013; Suomalainen et al., 2013; 
Wolfrum and Greber 2013).  Notably, HAdVs are well known to activate innate immunity 
by virtue of their pathogen-associated molecular patterns (PAMPs), such as capsid or 
DNA, and HAdV infection, and this leads to production of IFNs and inflammatory 
cytokines (Bruder and Kovesdi 1997; Suomalainen et al., 2001; Tibbles et al., 2002; 
Basner-Tschakarjan et al., 2006; Hartman et al., 2007b; Nociari et al., 2007; Lutschg et 
al., 2011). 
Entry 
The entry of HAdV into non-immune cells is initiated through binding of the fiber knobs to 
entry receptors and attachment factors (see Fig. 1B, and Arnberg 2012; Wolfrum and 
Greber 2013).  Entry pathways into immune cells, such as macrophages and dendritic 
cells may be different and could be modulated by cytokines or antibodies, and availability 
of low affinity high avidity receptors, such as scavenger receptors (Meier et al., 2005; 
Fejer et al., 2011; Khare et al., 2012; Mercer and Greber 2013).  Entry of HAdV-C2/5 into 
polarized epithelial cells from the apical side (facing the airways) is enhanced by 
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cytokines and chemokines, including interleukin 8 and tissue necrosis factor alpha 
(Lutschg et al., 2011).  The cytokines increase the availability of CAR and integrin 
receptors, which allows HAdV-C to enter along the well described pathways involving 
clathrin-mediated dynamin-dependent endocytosis (Wang et al., 1998; Meier et al., 2002; 
Gastaldelli et al., 2008).  The species B HAdVs use CD46 or desmoglein-2 as their major 
receptors, and engage in macropinocytosis for infectious entry (Gaggar et al., 2003; 
Sirena et al., 2004; Amstutz et al., 2008; Hall et al., 2009; Kalin et al., 2010; Wang et al., 
2011; Trinh et al., 2012).  How the CD46 pathway relates to the observation that HAdV-B 
suppress IFN-γ triggered production of the proinflammatory cytokine interleukin 12 is 
unknown (Iacobelli-Martinez et al., 2005).   
Endosomal escape of HAdV to the cytosol is important in triggering innate response, 
although the spectrum of host factors supporting this important step is incompletely 
known.  The endosomal escape process is not spontaneous but requires specific 
changes in the viral structure.  It is linked with the first steps of virus uncoating triggered 
by receptor motility on the cell surface (Helmuth et al., 2007; Burckhardt and Greber 
2009; Burckhardt et al., 2011).  This leads to structural changes at the vertices of the 
capsid and exposes the internal membrane lytic protein VI, which in turn facilitates the 
escape of the virus from an early endosome (Wiethoff et al., 2005; Wodrich et al., 2010; 
Burckhardt et al., 2011).  It should be emphasized here that the escape of both HAdV-B 
and HAdV-C serotypes is independent of endosomal pH, as recently demonstrated by a 
direct single cell, single virus penetration assay (Suomalainen et al., 2013).  This study 
used three different classes of chemical inhibitors to neutralize endosomal pH, the 
vacuolar proton pump inhibitor bafilomycin A, the protonophore niclosamide, and the 
lysosomotropic proton buffer ammonium chloride (Matlin et al., 1981; Bowman et al., 
1988; Jurgeit et al., 2012).  Earlier studies suggested that HAdV uses low pH for 
penetration and uncoating, for example based on the observation that incubation of 
viruses with low salt, EDTA and low pH for several hours leads to the dissociation of the 
pentons from the capsid (Laver et al., 1969).  The observation that low endosomal pH is 
not involved in HAdV infection, however, does not exclude that other ions in endosomes 
are important for the penetration process.  This has been suggested by observations that 
HAdV infection is sensitive to inhibitors of the sodium/potassium ATPase (Seth et al., 
1987), the sodium/proton exchanger (Meier et al., 2002; Amstutz et al., 2008; Kalin et al., 
2010) and the lysosomotropic agent ammonium chloride (Greber et al., 1993; 
Suomalainen et al., 2013), but not inhibitors of the vacuolar proton ATPase (Perez and 
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Carrasco 1994).   
The notion that infection is independent of endosomal pH is compatible with earlier 
results that the initial steps of virus uncoating, the shedding of the fibers and the 
exposure of the membrane lytic protein VI as well as protein VI mediated membrane lysis 
are independent of low pH (Greber et al., 1993; Wiethoff et al., 2005; Suomalainen et al., 
2013).  This means that the virus does not need to visit an acidic endosome to be 
infectious.  In fact, residing in a late endosome or lysosome bears the risk of degradation, 
as shown for the endosome escape defective HAdV-C2 mutant TS1 (Greber et al., 1996; 
Imelli et al., 2009).   
Infectious virus reaches the cytosol, and uses dynein / dynactin and microtubule-based 
transport to reach the nuclear membrane (Suomalainen et al., 1999; Leopold et al., 2000; 
Suomalainen et al., 2001; Mabit et al., 2002; Strunze et al., 2005; Bremner et al., 2009; 
Gazzola et al., 2009; Wodrich et al., 2010; Engelke et al., 2011).  It then docks to the 
nuclear pore complex and activates a kinesin-mediated capsid disruption program 
(Wisnivesky et al., 1999; Trotman et al., 2001; Strunze et al., 2011).  Although most of 
the particles are disrupted during this process, only a minor fraction of the viral DNA is 
imported into the nucleus, and as much as 50 to 90% stays behind in the cytosol with 
large cell to cell variability (Wang et al., 2013).  This suggests that the nuclear pore 
complex is a bottleneck for viral DNA import into the nucleus.  
 
HAdV vectors - a short glimpse 
Therapeutic HAdVs are genetically attenuated, or if wild type viruses are used, particular 
conditions preclude unintended virus replication and shedding to the environment 
(Lichtenstein and Wold 2004).  HAdV can be readily engineered as replicating or non-
replicating particles, and can be produced in high amounts under good manufacturing 
practice (GMP) (Lusky 2005), using established cell lines with a wide range of 
complementing properties (Kovesdi and Hedley 2010).  The first generation HAdV 
vectors were derived from early region 1 (E1)-deleted wild type viruses, mainly HAdV-
C2/5.  In addition to E1 deletion, second generation HAdV vectors were constructed with 
inactivated E2, E3 or E4 regions (Rein et al., 2006).  Helper-dependent gutless vectors 
had the entire viral genome deleted, except for the inverted terminal repeats that are 
crucial cis-acting elements for DNA packaging and replication (Ostapchuk and Hearing 
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2003; Raty et al., 2008).  Gutless viruses were designed to minimize the expression of 
viral genes, and thereby facilitate long term expression of therapeutic transgenes 
(Kreppel and Kochanek 2004).  Yet, even the gutless viruses elicit innate and adaptive 
immune responses that are directed against components of the vector or the therapeutic 
gene products (Schiedner et al., 2003; Stilwell et al., 2003).   
Innate responses elicited by viral DNA invariably shape the adaptive, pathogen specific 
immune response.  The adaptive immune response comprises virus-specific antibodies, 
which can neutralize the virus and limit the success of gene therapy.  Interestingly, the 
prevalence of antibodies against HAdVs varies largely depending on the serotype (Aste-
Amezaga et al., 2004).  For example, the wide-spread serotypes HAdV-C2/5 have a 
seroprevalence of 82 and 35%, whereas HAdV-B35 has close to 0%.  Hence, different 
HAdV serotypes may be uniquely suited for gene therapy.  Nonetheless, HAdV-C2/5 are 
more widely used than any other serotype in the clinics, despite their high 
seroprevalence (Toth et al., 2010; Yamamoto and Curiel 2010; Greber et al., 2013; 
Wolfrum and Greber 2013).  The major argument for pushing HAdV-C2/5 into clinical 
applications has been that their biology is well understood, and their seroprevalence can 
eventually be overcome by engineering strategies (see below).  In the next sections, we 
highlight factors and mechanisms that control innate immunity against HAdV in the 
plasma membrane, endosomes, and the cytosol.   
 
Soluble factors – local and systemic defense 
A major quest in gene therapy is targeting the cells of interest by systemic applications of 
the vector.  Upon intravascular injection, HAdV is normally filtered out of circulation 
before reaching its intended targets.  Vector sequestration occurs by clotting factors and 
Kupffer cells, sinusoidal endothelial cells or hepatocytes of the liver, immunoglobulins 
and defensins or the complement system (for reviews, see Haisma and Bellu 2011; 
Khare et al., 2011).  The soluble factors implicated in HAdV infection are depicted in Fig. 
2.  
Clotting factor X and the liver 
Many HAdVs bind the blood coagulation factor X (FX), and this is essential for liver 
transduction in mice (see Fig. 2, upper right, and Kalyuzhniy et al., 2008; Vigant et al., 
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2008; Waddington et al., 2008).  For HAdV-C5, binding of FX is of high affinity and 
occurs through solvent-exposed hypervariable loops of the viral capsid protein hexon.  
Recently FX interaction with the HAdV-C5 hexon was modeled using high resolution 
cryo-electron microscopy and led to identification of the T423-E424-T425 amino acid 
motif in hypervariable region 7 as critical for FX binding to virus.  Furthermore, a single 
amino acid substitution, T425A, completely abrogated FX binding to HAdV-C5 (Doronin 
et al., 2012).  This FX-binding-ablated virus failed to infect hepatocytes when injected in 
mice.  FX acts as a bridge for the virus to bind to particular classes of heparin sulfate 
proteoglycans on hepatocytes (Bradshaw et al., 2010).   
Another possibility is that FX shields the virus from attack by the complement system (Xu 
et al., 2013).  IgM antibodies and the complement system are well known to interact with 
HAdV-C5 and trigger inflammatory cytokine mediated reactions (Cichon et al., 2001; 
Shayakhmetov et al., 2005; Carlisle et al., 2009a).  However, complement-mediated 
HAdV elimination is most likely more complex in vivo, and may involve particular cell 
types, besides modification of the virus with complement factors, such as complement 
factor C3 (Tian et al., 2009).  For example, the temperature sensitive HAdV-C2 mutant 
TS1, which fails to uncoat and enter the cytosol, did not elicit the complement cascade 
upon intravenous injections in mice unlike wild type HAdV, although antibodies were 
binding to the TS1 capsid presumably similarly as to the wild type HAdV-C2 (Tian et al., 
2009).  Likewise, evidence indicates that canine adenovirus did not activate the human 
complement system in vitro, although it was recognized by cross-reacting antibodies in 
human sera (Perreau et al., 2007).  This suggested that virus interactions with the cells 
are critical for triggering complement in vivo.  Intriguingly, canine adenovirus and TS1 
both visited late endosomes in their entry pathways unlike HAdV-C2/5 (Greber et al., 
1996; Salinas et al., 2009; Suomalainen et al., 2013).  Recently, it was shown that high 
levels of immunoglobulins (Ig), including IgM negatively correlated with HAdV-C5 
transduction of hepatic cells in different mouse strains (Khare et al., 2013).  In animals 
lacking Kupffer cells, HAdV-C5 transduction was high, even in presence of Ig, and partial 
reconstitution of IgM into Rag knock-out animals reduced HAdV transduction of hepatic 
cells.  These data suggested a model where IgM mediate the clearance of HAdV-C5 by 
Kupffer cells.   
Immunoglobulins and TRIM21 - extracellular and intracellular defense 
Antibodies, in particular Igs protect against lethal infections by viruses including HAdVs 
(Moore et al., 2004).  They emerge mainly from plasma cells, marginal zone B cells and 
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other innate B cells, and are directed against specific epitopes of viral proteins or other 
biologicals.  Igs normally recognize their targets in extracellular space, block their 
biological functions and direct them to degradation in immune cells for antigen 
presentation.  However, in some instances antibody inhibition against viruses is mediated 
by just a single antibody per virion.  The inhibition occurs post adsorption to cells, or 
depends on IFN (see Fig. 2, lower left, and Wohlfart 1988; Vrijsen et al., 1993; 
Burdeinick-Kerr et al., 2007).  It was later shown that a non-replicating HAdV-C5_dE1 
loaded with antibodies can access the cytosol of non-immune cells, and there the virus-
antibody complex recruited tripartite motif-containing protein 21 (TRIM21) to the Fc 
portion of an IgG or IgM (Mallery et al., 2010).  Similar results were recently reported for 
a replicating mouse adenovirus (Watkinson et al., 2013).  The cytosolic antibody receptor 
TRIM21 is a RING finger E3-ubiquitin ligase of a family of nearly 100 tripartite motif 
genes in the mammalian genome.  It acted together with the host AAA ATPase valosin-
containing protein (VCP) and dismantled the viral capsid, thereby enabling virus 
presentation to the proteasome, and blocking infection (Hauler et al., 2012). 
Importantly, TRIM21 has been shown to protect wild type mice from lethal challenge with 
mouse adenovirus (Vaysburd et al., 2013).  Protection involved upregulation of TRIM21, 
and TRIM21 stimulated IFN response and pro-inflammatory cytokines through NF-кB, 
activator protein 1 (AP1) and IFN regulatory factor (IRF) 3, IRF5 or 7 (Mcewan et al., 
2013).  Interestingly, TRIM21 mediated innate immunity was triggered by both DNA and 
RNA viruses, as well as bacteria.  This suggests that the TRIM21-antibody machinery is 
unusually broad in detecting danger signals.  It may act independently of other PAMP 
receptors, or at least upstream of them.  Regardless, the machinery for intracellular 
antibody mediated degradation of PAMPs is present in most human tissues, and 
represents an example of encapsulated immunity as opposed to systemic immune 
surveillance.  
Defensins – for local defense 
Another line of defense that acts locally rather than systemically are defensins, which are 
abundant anti-microbial peptides, that occur in high concentrations at micromolar to 
millimolar ranges in extracellular fluids of nasal, lung or vaginal epithelia (reviewed in 
Lehrer and Lu 2012).  Defensins are effective against viruses, as originally shown for 
herpes viruses, vesicular stomatitis virus and influenza virus with cell supernatants from 
human neutrophils (Ganz et al., 1985; Daher et al., 1986; Wilson et al., 2013).  Later it 
was shown that defensins also protect against non-enveloped viruses by directly 
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binding to HAdV or human papilloma virus and blocking viral uncoating or signaling (Buck 
et al., 2006; Smith and Nemerow 2008).  Defensins are small cationic peptides of 30 to 
40 amino acids.  Humans express a broad range of α and β-defensins.  α-defensins are 
mostly expressed from human neutrophils but also monocytes / macrophages, B and T 
cells and immature dendritic cells (Selsted and Ouellette 2005), whereas β-defensins are 
released from epithelial cells in skin and mucosal tissue (Pazgier et al., 2006).  
The α-defensin human defensin 5 inactivates HAdV-C by binding to intrinsically 
disordered regions of the viral capsid involving the RGD loops of penton base at the 5-
fold icosahedral axis (see Fig. 2, lower left, and Flatt et al., 2013).  This interferes with the 
dynamics of the capsid and blocks the release of the membrane lytic protein VI from the 
capsid (Smith and Nemerow 2008; Smith et al., 2010a; Snijder et al., 2013).  At present it 
is not known if HAdV infections induce the expression of defensins, as has been reported 
for RNA viruses or cells transfected with poly (I:C) implicating cytosolic detection of 
double stranded RNA as a trigger for defensin induction (reviewed in Wilson et al., 2013).  
Future research is needed to reveal more of the intricate mechanisms by which enteric 
and neutrophil defensins modulate HAdV infections.   
 
Toll-like receptors 
HAdVs are also controlled by membrane-bound proteins.  The mammalian homologues 
of the Drosophila Toll-like receptors (TLR) are a class of pattern recognition receptors 
(PRRs) detecting and responding to PAMPs and triggering innate immune reactions 
(Beutler et al., 2006; Kawai and Akira 2011; Thompson et al., 2011).  There are ten 
human TLRs and 12 murine TLRs.  Some TLRs are predominantly on the plasma 
membrane, such as TLR1, 2, 4, 5, 6, and others in endosomal compartments, for 
example TLR3, 7, 8, 9 and 10.  All human TLRs require the adaptor myeloid 
differentiation primary response gene 88 (MyD88) for innate signaling, albeit at different 
extent (Takeda and Akira 2004).  Transcription profiling of plasma cells and liver from 
mice inoculated intravenously with HAdV-C2 showed that a large fraction of the genes 
that were transcriptionally upregulated depended on MyD88, suggesting that at least one 
TLR senses HAdV-C2 and signals through MyD88 in a mouse model (Hartman et al., 
2007b).  This was confirmed in cell cultures (Hartman et al., 2007a).  The TLR response 
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also activates nuclear factor-kappa B (NF-κB), MAP kinases and IRFs.   
Specifically, TLR9 was found to sense HAdV-B in peripheral blood mononuclear cells 
and plasmacytoid dendritic cells (pDCs) (see Fig. 2, top right, and Sirena et al., 2004; 
Iacobelli-Martinez and Nemerow 2007).  TLR9 detects non-methylated CpG rich DNA.  
Since CAR tropic HAdV were not sensed by TLR9 in these experiments, it is possible 
that CAR plays no role in pDCs and other uptake and signaling pathways specific for 
HAdV types are used in pDCs.  
The production of pro-inflammatory cytokines was also determined in primary 
macrophages inoculated with helper-dependent (gutless) HAdV-C5 (Cerullo et al., 2007).  
TLR9 knock out mice had a reduced innate response to helper-dependent HAdV-C5 
upon intravenous injection of the vector.  In addition to TLR9, TLR2 also contributes to 
innate responses against HAdV.  TLR2 detects triacylated lipoproteins from bacteria.  
TLR2 knock out mice showed reduced NF-кB activation and humoral responses to HAdV 
vectors (Appledorn et al., 2008).  Notably, MyD88 knock-out was, however, not sufficient 
to silence acute and adaptive responses to HAdV, indicating that other mechanisms than 
TLR signaling are important in innate and adaptive responses to HAdV (Fejer et al., 
2008).   
In addition, there is evidence that HAdV-C complexed with FX activates innate immunity 
through TLR4, and mounts an IL1-β inflammatory response (Doronin et al., 2012).  
Interestingly, a HAdV-C variant ablated in FX binding failed to trigger the inflammasome 
response, but triggered other innate responses.  This suggests that innate immune 
reactions depend on both the nature of the vector and soluble factors attached to the 
vector.  It remains to be determined if differential responses are connected to trafficking 
pathways, such as endocytic uptake or subcellular location of subviral structures in 
immune or non-immune cells (Mercer and Greber 2013; Wang et al., 2013), or if blood 
factors bound to pathogens have direct immune signaling potential.   
 
Lectin receptors 
Lectin receptors (LRs) are a heterogeneous family of PRRs responding to DAMPs 
typically through direct binding to sugars of the pathogen.  LRs are soluble proteins that 
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can be released to the extracellular space, such as galectins which bind to mannan 
sugars, or they are anchored in the plasma membrane, for example the mannose-
receptor dectin-1 (Geijtenbeek et al., 2004; Cerliani et al., 2011).  LRs are frequently 
found on immune cells, such as conventional and pDCs, and are implicated in signaling 
crosstalk with TLRs which is thought to enhance immunity (reviewed in Kawai and Akira 
2011; Osorio and Reis E Sousa 2011).   
Two LRs have been implicated in HAdV infection, sialic-acid-binding immunoglobulin-like 
lectins (Siglecs) and galectins (Fig. 2, top left).  Siglecs are trans-membrane proteins 
involved in innate and adaptive immune responses.  Similar but not identical to the 
human Siglec-8, the fiber knob of canine adenovirus was found to bind to terminal sialic 
acid on complex sugars containing galactose and N-acetyl glucosamine, although Siglec-
8 and canine adenovirus fiber knob do not share sequence similarity (Rademacher et al., 
2012).  It can be speculated that sialic acid is an attachment site for canine adenovirus, 
similar to earlier reports that HAdV-C2/5 binds to sialic acid residues of heparin sulfate 
proteoglycans, although the functional implication remains unknown (Dechecchi et al., 
2000; Dechecchi et al., 2001).  Possibly, the sialic acid residues on the cell surface exert 
an inhibitory effect on HAdV infection.  For example, it was reported that expression of 
Muc1, which is an O-glycosylated membrane protein and part of the protective mucous 
barrier on the epithelial surface, reduced the infection of Madin Darby Canine Kidney 
(MDCK) cells with HAdV-C (Arcasoy et al., 1997).  This inhibition was abrogated by 
treatment of cells with sialidase thus suggesting that extracellular sialic acid residues 
inhibit HAdV infection.  
The most prominent members of endosomal LRs implicated in HAdV infection are 
galectins (Gals).  Gals are a family of β-galactoside-binding proteins with domains for 
carbohydrate recognition.  Gals function in innate immunity and surveillance of innate 
immune processes (Rabinovich and Toscano 2009).  They are normally localized in 
intracellular compartments or the cytosol, and can be secreted by a non-conventional 
mechanism independent of a leader peptide (Seelenmeyer et al., 2005; Schneider et al., 
2010).  Interestingly, Gal3 puncta have been shown to colocalize with incoming HAdV-
C5, and in some cases these colocalization events were also positive for exposed protein 
VI (Maier et al., 2012).  This together with experiments where mCherry-tagged Gal3 was 
ectopically expressed, this was interpreted to suggest that Gal3 detected galactose sugar 
residues on ruptured endosomal membranes during HAdV-C5 entry.  Whether these 
membranes were broken or not has remained unknown, however.  However, it is 
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possible that the colocalization of Gal3 with HAdV-5 involved vesicular transport, for 
example endosomal or plasma membrane localized Gal3.  Regardless of how Gal3 
colocalized with HAdV-C5, proteomics analyses showed that both Gal1 and Gal3 were 
strongly down-regulated in human lung epithelial cells upon infection with HAdV-C5 or B3 
(Trinh et al., 2013).  This reinforces the notion that HAdV drastically alters the function of 
Gals.  It remains to be seen if Gals are degraded, or released from infected cells by non-
conventional secretion.  It is noteworthy that also newly synthesized penton base and 
fiber proteins in HAdV-C2 infected A549 cells are secreted by a non-conventional 
mechanism, and this secretion has been suggested to aid virus shedding from polarized 
epithelial cells (Walters et al., 2002; Trotman et al., 2003).   
 
Cytosolic DNA - triggering inflammasomes 
Besides TLRs and LRs, most mammalian cells have TLR-independent mechanisms to 
detect cytosolic viral DNA.  These pathways can be pro-inflammatory and independent of 
IRFs.  They enhance anti-viral defense, and involve nucleotide-binding oligomerization 
domain (NOD)-like receptors (NLRs), the core of the inflammasomes.   
Myeloid cells derived from granulocyte precursors in the bone marrow or the spinal cord 
contain a multi-protein complex of NLR family proteins, the so called NLR-pyrin domain 
containing protein (NLRP) inflammasomes (reviewed in Tschopp et al., 2003; 
Bauernfeind and Hornung 2013).  NLRP inflammasomes further consist of NACHT, LRR 
and PYD domains-containing protein 1 (NALP1), apoptosis-associated speck-like protein 
(ASC), caspase 1 and yet other proteins.  They comprise the classical NLRP1 and 
absent in melanoma 2 (AIM2), a PYHIN protein that leads to caspase-1 activation and 
maturation of IL1β.  The AIM2-like receptors (ALR) sense double stranded DNA via the 
HIN200 domain of AIM2, and interact with the Caspase-1 adaptor protein via a PYD 
domain (Hornung et al., 2009).  Inflammasome activation triggers inflammatory 
responses via NF-κB signaling, converts pro-IL1β and pro-IL18 into IL1β and IL18 
respectively, and can lead to DNA fragmentation, membrane pore formation and 
eventually cell death by pyroptosis (reviewed in Fink and Cookson 2005).   
NLRs are cytosolic DNA sensing proteins.  They are composed of a central nucleotide-
binding (NOD or NACHT) domain responsible for ATP-dependent self-oligomerization, 
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a C-terminal leucine-rich repeat (LRR) domain that senses the presence of a ligand and 
a variable N-terminal interaction domain that mediates protein-protein interactions, mainly 
via a CARD or pyrin domains (PYD).  NOD1-4 contain a CARD domain, NOD5 lacks an 
N-terminal domain, and the NALPs have a PYD domain.  Signaling downstream of NLRs 
leads to the formation of inflammasomes, and this may involve microtubules as 
suggested for NLRP3 (Misawa et al., 2013).  In addition, NLRs cooperate with TLRs to 
regulate inflammatory and apoptotic responses.  
In HAdV infected myeloid cells, two types of inflammasomes are activated, AIM2 and 
NALP3 (Fig. 2, lower right).  HAdV DNA is sensed through AIM2 (Stein and Falck-
Pedersen 2012; Stein et al., 2012), the TRAF family member-associated NF-κB activator 
(TANK)-binding kinase 1 (TBK1) (Nociari et al., 2007), the NALP3-ASC-caspase-1 
complex (Muruve et al., 2008), or a yet unknown cytosolic DNA sensor in conventional 
DCs (Zhu et al., 2007).  HAdV-C5 activation of the NLRP3 inflammasome was shown in 
THP1 cells conditioned with phorbol esters, and this lead to the production of IL1-β and 
the release of lysosomal cathepsin B to the cytosol (Barlan et al., 2011a; Barlan et al., 
2011b).  Interestingly, cathepsin B release did not correlate with lysosomal localization of 
the virus, suggesting that cathepsin relocalization occurs by an indirect mechanism.   
The inflammasome was not only triggered in myeloid cells but also in the skin.  HAdV-
C5_dE1 vector application or liposome mediated transfection of purified HAdV-C5_dE1 
DNA to full skin ex vivo or in vivo, or into HaCaT or HKT cells lead to the expression of 
inflammatory cytokines and type 1 IFN-β (Steinstraesser et al., 2011; Schulte et al., 2013).  
This was dependent on the DNA sensors AIM2, NALP3, and the RNA sensor MDA5.  
The transient knock-down of AIM2, NALP3, MDA5 and to a small extent also the DNA-
dependent activator of IFN regulatory factors (DAI) increased viral expression of GFP 
from the major cytomegalovirus promoter.  This suggests the feasibility of HAdV gene 
transfer into immunosuppressed skin.   
 
Cytosolic DNA - pathway to interferon 
DNA sensors – definition and function 
Foreign nucleic acids can be a major insult to the integrity and hereditary programs of 
cells.  A major question is how cells distinguish between self and non-self nucleic 
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acids.  One point of distinction is recognizing structural features, for example, cytosolic 
double stranded RNA with 5’-triphosphate groups is sensed by RLRs, such as RIG-I 
(Weber et al., 2013).  Another point of distinction is the localization of the nucleic acid.  
Extracellular nucleic acids are detected by membrane-associated TLRs, such as TLR3, 7 
and 8 binding to RNA, and TLR9 to double stranded DNA.  But for cytosolic DNA, the 
distinction by localization is not generally true, since DNA sensing occurs in both the 
nuclear and the cytosolic compartment, as shown for herpes virus (Li et al., 2012; Orzalli 
et al., 2012).  It remains possible that innate signaling from cytosolic DNA occurs on 
specialized cytoplasmic structures or organelles.    
The cell requires sensors for self versus non-self distinction of DNA.  Sensors can be 
proteins with receptor function binding to DNA.  These sensors induce an IFN or 
inflammatory cytokine responses upon DNA exposure.   
Besides TLRs and inflammasome-associated DNA sensing, a range of cytosolic proteins 
have been implicated in protecting cells against double stranded DNA, as shown, for 
example, in early studies with HAdV and myeloid cells (see Fig. 2, lower left, and Nociari 
et al., 2007; Zhu et al., 2007; Fejer et al., 2008; Nociari et al., 2009).  Cytosolic proteins 
implicated in IFN signaling upon DNA challenge include DAI, DNA-dependent protein 
kinase (DNA-PK) sensing linear double stranded DNA and repairing DNA double 
stranded breaks, RNA polymerase III converting cytosolic DNA into double stranded RNA 
for RLR signaling, IFN-γ inducible protein 16 (IFI16, also known as p204) a member of 
the Pyrin family, as well as DDX41, and cGAS (for reviews, see Weitzman et al., 2010; 
Rathinam and Fitzgerald 2011; Ferguson et al., 2012; Xiao and Fitzgerald 2013).   
So far, there are only three proteins that appear to fulfill the strict definition of a DNA 
sensor, IFI16, DDX41 and cGAS.  For HAdV, DDX41 and cGAS have been implicated.  It 
is possible that viral interference blocks particular DNA sensing pathways, or that 
features of HAdV-DNA camouflage recognition.  For example, the covalent attachment of 
the terminal protein to the 5’ ends could prevent DNA-PK activation, or core protein VII 
could block IFI16 (Zhao et al., 2009; Karen and Hearing 2011).   
RNA polymerase III  
The adenoviral genome encodes two RNA molecules, virus associated RNA I (VA-I) and 
VA-II.  VA RNAs block the IFN induced protein kinase R (PKR), which relieves protein 
synthesis inhibition in the anti-viral state (Ma and Mathews 1996).  The VA-I and VA-II 
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genes are transcribed by host RNA polymerase III (Pol III) into short noncoding RNAs of 
157 and 158 nucleotides, respectively, and both have extensive secondary structures 
(Akusjarvi et al., 1980).  Upon transfection, VA-I and VA-II were found to bind to RIG-I, a 
DEAD box helicase that binds to 5’-triphosphorylated double stranded RNA (see Fig. 2, 
lower right, and Minamitani et al., 2011; Weber et al., 2013).  HAdV-C5_dE1 induced a 
biphasic production of type 1 IFN (IFN-β) in human gastric cancer NU-GC-3 cells 
(Minamitani et al., 2011).  Silencing of RIG-I, IRF3 or UV-inactivation of the virus reduced 
the late response at 48-60 h post infection, whereas the early response at 12-24 h post 
infection was not affected.  This suggests that RIG-I and IRF3 are not required for a type 
1 IFN response in early infection, but triggered by late events, which coincide with the 
expression of VA-I and VA-II.  This makes it unlikely that HAdV DNA is subject to 
transcription by Pol III.  This notion is supported by the observation that the immediate 
early HAdV transactivator E1A, which is present throughout the early phase of infection 
blocks Pol III transcription (Sollerbrant et al., 1993).  
For vaccinia virus and herpes virus infections, cytoplasmic Pol III was reported to 
transcribe double stranded viral DNA to 5’-triphosphorylated RNA, which was sensed by 
RIG-I and turned into a type 1 IFN response through mitochondrial anti-viral signaling 
protein (MAVS), also called Ips1 (IFN-β promoter stimulator) / VISA (virus induced 
signaling adapter) / Cardif (Chiu et al., 2009).   RIG-I (or MDA5) interaction with MAVS 
occurs via a caspase recruitment domain (CARD), and activates the protein kinases 
IKKA and IKKB, and NF-κB translocation to the nucleus.  In cell types defective of other 
DNA sensing pathways (presumably cGAS / STING), the Pol III inhibitor ML-60218 
blocked the production of type 1 IFN upon exposure to herpes viruses or Legionella 
bacteria, suggesting that Pol III can be part of an innate mechanism in the cytosol.  
DDX41 
DDX41 is a member of the DEXD box family of ATP-dependent helicases, and a 
cytosolic DNA sensor in myeloid dendritic cells (mDCs) that works together with STING 
(Zhang et al., 2011).   The sensor function depends on the Walker A and B motifs and 
directly binds to STING, and this is required for signaling together with DDX41 binding to 
DNA.  Upon stimulation of cells with poly (dA:dT) STING relocates from the ER to a 
vesicular compartment where it colocalizes with DDX41.  Together, STING and DDX41 
signal through TBK1, mitogen-activated protein kinases and NF-κB, and trigger an IFN 
response.  Knock-down of DDX41 in mouse DCs by RNA interference strongly reduced 
the type 1 IFN production upon challenge of cells with HAdV, similar to the knock-down 
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of STING (see Fig. 2, lower left, and Zhang et al., 2011).  Accordingly, the knockdown of 
DDX41 in RAW 264.7 cells reduced the levels of phosphorylated IRF3 following 
inoculation with replication-defective HAdV-C5 (Stein and Falck-Pedersen 2012).  The 
role of IRF7 was not addressed in this study, although IRF7 was critical for type 1 IFN 
induction by HAdV in mice (Fejer et al., 2008).  Collectively, the data suggest that DDX41 
is a cytoplasmic sensor that detects HAdV DNA, and is involved in triggering an antiviral 
DNA response in certain cells.      
cGAS 
cGAS is a nucleotidyl-transferase involved in sensing cytosolic DNA.  Similar to IFI16, 
cGAS recognizes the DNA via the sugar backbone.  This leaves open the possibility that 
cGAS also detects cellular DNA in the cytosol (Jin et al., 2012; Gao et al., 2013).  cGAS 
catalyzes the formation of cyclic guanosine monophosphate–adenosine monophosphate 
(cGMP-AMP, short cGAMP) from ATP and GTP in a DNA-dependent manner (Sun et al., 
2013).  cGAMP was identified in Vibrio cholerae bacteria where it functions in chemotaxis 
and colonization (Davies et al., 2012).  In mammalian cells, cGAMP binds the adaptor 
protein STING with high affinity, and leads to the activation of TBK1, IRF3 and the 
production of IFN-β (Ablasser et al., 2013a; Zhang et al., 2013).  The cGAS / STING 
pathway is active in epithelial, endothelial and myeloid cells, and is probably the most 
prominent pathway for protecting cells from untypical DNA.  Interestingly, the transfer of 
the cGAMP second messenger between cells via gap junctions confers bystander effects 
from infected to uninfected neighboring cells (Ablasser et al., 2013b).   
Recently, it was shown that HAdV DNA is sensed by cGAS which triggers a major IFN 
response in murine RAW264.7 macrophage-like cells (see Fig. 2, lower left, and Lam et 
al., 2014).  This response is likely related to the observation that incoming HAdV-DNA is 
not only delivered to the nucleus, but also to the cytosol (Wang et al., 2013).  
STING - downstream effector and signaling hub 
In order to establish an innate immune response, upstream sensors amplify signals by 
engaging downstream cascades.  These cascades involve adaptor molecules, MAVS, 
MyD88, TIR-domain-containing adapter-inducing IFN-β (TRIF), or stimulator of IFN 
genes (STING, also known as trans-membrane protein 173).  This triggers activation of 
transcription factors, for example NF-κB, AP1, IRF3/7 or signal transducer and activator 
of transcription 1/2 (STAT1/2), and eventually leads to a type 1 IFN response.  But this 
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response is not guaranteed, since the sensors and downstream effector proteins are 
often expressed in a cell type specific manner, and viruses actively interfere with the 
signaling cascade.  For example, it was shown that replication-defective HAdV-C5_dE1 
is efficiently sensed in RAW264.7 macrophages, as indicated by phosphorylation of IRF3 
and STAT1/2, but did not elicit a response in FL83B hepatocytes (Stein et al., 2012).  
The reason for lack of DNA signaling in the hepatocytes was apparently the lack of 
STING, as shown by ectopic expression of STING and RNA interference.  STING 
localizes to the endoplasmatic reticulum (ER) in close association with mitochondria 
(Ishikawa and Barber 2008).  STING senses cGAMP, dimerizes and thereby activates 
type 1 IFN through TBK1 mediated phosphorylation of IRF3 and STAT6.  STING can be 
activated by binding to DDX41, DAI or IFI16.  IFI16 was shown to directly bind viral DNA, 
and STING was recruited to IFI16 after DNA stimulation (Unterholzner et al., 2010).  
Phosphorylated IRF3 and STAT6 dimerize and enter the nucleus for transcriptional gene 
activation (Tanaka and Chen 2012).  Importantly, STING can be down-regulated by the 
E3-ubiquitin ligase ring finger protein 5 (RNF5) (Zhong et al., 2009).   
It is interesting to note that HAdV-C5 was reported to induce necrosis of liver CD68-
positive macrophages, independent of STING, through a mechanism involving IRF3 
upstream of transcription (Di Paolo et al., 2013).  This necrosis pathway involved the 
permeabilzation of endosomes or the plasma membrane, as suggested by the 
observation that the endosome-escape defective HAdV-C2_TS1 did not induce necrosis 
(Imelli et al., 2009; Di Paolo et al., 2013).  In this scenario, IRF3 is not acting on STING, 
or triggering apoptosis or IFN signaling, but rather involved in necrotic cell death, which 
may be a pathway not involving STING. 
 
Autophagy – pro-viral or anti-viral? 
Beyond controlling inflammasomes, TBK1 plays important roles in triggering innate 
immune responses against double stranded DNA, which critically depends on stimulator 
of IFN genes (STING) (Saitoh et al., 2009).  STING is an ER associated membrane 
protein.  Upon sensing cytosolic DNA, STING moves from the ER to the Golgi, and 
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then associates with TBK1 on punctate structures in the cytoplasm, which contain the 
autophagy-related gene 9a (ATG9a).  The structures lack ATG5 and ATG7, suggesting 
that they are not double membrane autophagosomes.  Cells with depleted ATG9a have 
enhanced STING-TBK1 complexes, and aberrantly high activation of innate immunity 
upon sensing cytosolic DNA, and TBK1 association in this compartment is key for an IFN 
response.  Hence nonconventional autophagy membrane trafficking down-tunes innate 
immunity upon DNA sensing.   
Autophagy also negatively regulates the secretion of IL1-β downstream of inflammasome 
activation, down-tunes inflammatory responses, and potentially enhances infection 
(Deretic et al., 2012).  Autophagy augments unconventional secretion of signal-peptide 
lacking proteins (Nickel and Rabouille 2009; Dupont et al., 2011), but it is unknown if it 
accounts for the loss of Gal1 and Gal3 from HAdV infected cells (see Fig. 2, lower left, 
and Trinh et al., 2013).   
Classical autophagy eliminates long-lived organelles and other cytosolic substrates by 
isolating and delivering them to lysosomes (for reviews, see Munz 2011; Deretic et al., 
2012; Randow and Munz 2012).  Autophagy was originally found to be up-regulated 
under nutrient starvation in order to recycle cellular constituents and maintain 
homeostasis (for a historical review, see Yang and Klionsky 2010).  There are three 
major forms of autophagy, chaperone-mediated autophagy, micro-autophagy and macro-
autophagy.  Chaperone and micro-autophagy directly deliver substrates into lysosomes, 
whereas macro-autophagy engulfs cytosolic substrates with a double-lipid membrane, 
and these structures then fuse with lysosomes.  Engulfing bacteria or viruses by macro-
autophagy is termed xenophagy (from greek “strange-eating”), and limits infection 
(reviewed in Levine et al., 2011). 
The autophagosomal isolation membrane around cytoplasmic contents is formed by 
recruitment of the class III phosphatitylinositol-3-OH kinase complex at ER-mitochondria 
contact sites (Hamasaki et al., 2013).  This consists of Vps34, Vps15, beclin-1 (ATG6) 
and ATG14, which recruits further effector proteins for the generation of the isolation 
membrane.  Elongation of this structure is mediated by two ubiquitin-like conjugation 
systems.  First, ATG12-ATG5 is produced by the E1-like activity of ATG7 and E2-like 
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activity of ATG10 together with ATG16L1.  Secondly, E1 and E2-like activities of ATG7 
and ATG3 respectively lead to the conjugation of ATG8 homologues, for example 
microtubule-associated protein 1A/1B-light chain 3 (LC3), with phosphatidyl-
ethanolamine (Levine et al., 2011).  These serve for the elongation of the structure and 
loading of cargo that is bound to LC3-interacting proteins, such as p62 or Alfy (Bjørkøy et 
al., 2005).  Subsequently, the ATG5-ATG12-ATG16L1 complex dissociates from the 
outer phagosomal membrane upon completion of the compartment.  Eventually the 
autophagosome matures by fusion with late endosomes and lysosomes in a Rab7-
GTPase dependent manner, and lysosomal hydrolases degrade luminal contents as well 
as the inner autophagosomal membrane (Mizushima et al., 1998; Jager et al., 2004).  
Normally, airway cells are under high oxygen pressure, which induces adaptive 
autophagy (Ryter and Choi 2010).  Respiratory pathogens, such as HAdV, have likely 
adapted to take advantage of such conditions.  Indeed, it has been shown that adaptive 
autophagy, for example induced by starvation in airway cell cultures enhanced the 
expression of early HAdV-C2 genes and virus production (see Fig. 2, lower left, and Zeng 
and Carlin 2013).  Conversely, inhibition of autophagy decreased viral yields, possibly by 
lowering the recycling of nutrients (Rodriguez-Rocha et al., 2011).  It is possible that 
autophagy-mediated infection enhancement is associated with fusion of early endosomes 
with autophagosomes.  Some of the fused compartments, so called amphisomes were 
positive for HAdV-C2, suggesting that HAdV-C2 may use amphisomes to break free into 
the cytosol (Zeng and Carlin 2013).  This aspect of infection could be enhanced by 
autophagy, and deserves further attention.   
In other instances, autophagy was found to be induced, for example, in human glioma 
cells inoculated with a second generation HAdV-C5 vector dl922-947 (Mcneish et al., 
2005).  dl922-947 has a small E1A deletion in the conserved region 2, and a deletion in 
the E3B locus (Heise et al., 2000).  When autophagy was reduced with broad range 
inhibitors, such as chloroquine or 3-methyladenine, the cytotoxic effects of dl922-947 
were enhanced in cell cultures and mouse xenograft models (Mcneish et al., 2005).  
Cancer cells may use autophagy to enhance their survival, and defend against HAdV 
vectors.  It is possible that E3B tunes autophagy, and E3B is missing in dl922-947.  E3B 
is also known to contain RIDα (receptor internalization and down-regulation α), an 
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integral membrane protein of early and late endosomes (Crooks et al., 2000).  It acts as a 
GTP-Rab7 mimic interacting with Rab7 effectors, such as Rab7-interacting lysosomal 
protein or oxysterol-binding protein–related protein 1 (Shah et al., 2007).  Interestingly, 
RIDα was shown to rescue the cholesterol storage phenotype of Niemann-Pick disease 
type C mutant fibroblasts, and is involved in lipid droplet formation (Cianciola and Carlin 
2009; Cianciola et al., 2013).  One can envisage that a combination of autophagy 
inducing compounds together with HAdV may enhance oncolytic efficacy of viral 
therapies (Rodriguez-Rocha et al., 2011; Cheng et al., 2013). 
 
Countering the IFN response – HAdV early proteins and 
noncoding RNAs 
The early proteins of HAdV, including proteins from the early region 1 (E1), E3 and E4 
are the best studied host innate response antagonists (reviewed in Weitzman and 
Ornelles 2005).  In addition, the VA-RNAs antagonizing PKR and the structural protein VI 
have been described in attenuating innate anti-viral response (Burgert et al., 2002; 
Schreiner et al., 2012).  For a schematic representation, see Fig. 2.  
E1A proteins 
Early analyses have indicated that multiple HAdV genes interfere with host immunity.  Of 
particular note is the early region 1A (E1A) protein, the immediate early viral 
transactivator.  E1A is transcribed and alternatively spliced soon after arrival of the viral 
DNA genome in the nucleus.  E1A proteins encoded by 9S, 12S and 13S mRNAs exert a 
large array of effects, including control of the cell cycle, apoptosis, immune evasion, 
tumorigenesis and viral gene expression (for reviews, see Berk 1986; White 1993; 
Burgert et al., 2002; Frisch and Mymryk 2002).  E1A changes the epigenetic program of 
the cell within just a few hours of infection (Ferrari et al., 2008; Horwitz et al., 2008).  
E1A potently blocks type 1 IFN inducible gene expression (see Fig. 2, upper left, and 
Ackrill et al., 1991; Gutch and Reich 1991; Kalvakolanu et al., 1991).  The inhibitory 
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activity of E1A depended on the conserved region 1 (CR1) domain.  In addition, E1A 
blocks the induction of HLA class II genes by type 2 IFN-γ, and IFN-β mRNA in response 
to double-stranded RNA, and this involves a block in transcription complex formation 
(Kalvakolanu et al., 1991).  Specifically, E1A targeted the interferon-alpha-stimulated 
transcription factor 3 (ISGF3) consisting of Stat1, Stat2 and p48 by inhibiting p300 and / 
or cAMP response element-binding protein (CREB)-binding protein (CBP) (Bhattacharya 
et al., 1996).  P300/CBP is targeted by E1A, and this leads to repressed Stat2 
transactivation.  Another mechanism by which E1A blocks IFN stimulated gene (ISG) 
transcription is by interference with histone 2B mono-ubiquitination through the ubiquitin 
ligase RNF20/hBRE1, which is necessary for ISG transcription (Fonseca et al., 2012).  
E1A also activates viral transcription by recruiting the scaffold protein hPAF1 to 
RNF20/hBRE1, and this boosts viral infection (Fonseca et al., 2013).   
Furthermore, E1A interacts with the 20S and 26S proteasome, in particular the 
immunoproteasome, which emerges from regular proteasomes upon IFN-γ treatment 
(Berhane et al., 2011).  E1A also interferes with the presentation of peptides to the 
immunoproteasome by interacting with the MECL1 of the immuno-proteasome, and 
down-regulating MECL1 expression.  This interception of innate immunity reduces 
antigen presentation on infected cells and enhances the survival.  Collectively, all this 
illustrates the great versatility of E1A, which is an intrinsically disordered protein that 
works as a major functional hub in a context dependent manner (Ferreon et al., 2013).   
E1B proteins 
In addition to E1A, a significant number of other HAdV gene products modulate host 
immune responses, and thereby help the virus to persist in an infected host (Mahr and 
Gooding 1999; Wold et al., 1999).  Most prominently, the E1B-19K and E1B-55K proteins 
expressed early in infection antagonize E1A induced p53-mediated apoptosis (Sabbatini 
et al., 1995; Teodoro and Branton 1997).  In addition, E1B-55K interferes with the 
induction of IFN-inducible genes, as E1B-55K null viruses are exquisitely sensitive to 
type 1 IFN (Chahal and Flint 2012; Chahal et al., 2012).  The transcriptional repression 
mechanism by E1B-55K occurs through the tumor suppressor protein p53, which 
interacts with E1B-55K (Chahal et al., 2013).   
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In addition, E1B-55K together with the HAdV E3-ubiquitin ligase the early region 4 open 
reading frame protein 6 (E4orf6) protein triggers proteasome-mediated degradation of 
defense factor death-domain-associated (Daxx) (Schreiner et al., 2010; Schreiner et al., 
2013a).  Daxx restricts viral gene expression by forming a complex with the ATP-
dependent helicase (ATRX).  The degradation of Daxx thereby relieves a viral 
transcription block, and allows viral gene expression.  It was also reported that the virion 
protein VI inhibited Daxx (Schreiner et al., 2012).  Since protein VI is rapidly degraded 
during virus entry and the mode of Daxx inhibition by protein VI does not seem to involve 
Daxx degradation, the stoichiometry of incoming protein VI does not match that of Daxx, 
particularly since Daxx is induced by IFN (Greber et al., 1993; Gongora et al., 2001; 
Burckhardt et al., 2011; Schreiner et al., 2012).  
E1B-55K also works in complexes with E4 proteins to block anti-viral innate reactions. 
Together with E4orf3, E1B-55K relocates the Mre11, Rad50, Nbs1 (MRN) complex and 
thereby precludes the formation of concatamers and DNA damage signaling during viral 
replication, thus increasing virus yield from infected cells (Stracker et al., 2002; Evans 
and Hearing 2003; 2005; Stracker et al., 2005; Carson et al., 2009).  Yet another 
complex of E1B-55K functions in enhancing viral gene expression.  E1B-55K-E4orf6 and 
a cullin based E3 ubiquitin ligase targets the anti-viral factor SPOC1 for degradation by 
the proteasome (Schreiner et al., 2013b).  SPOC1 normally works in DNA damage 
response. 
E3 proteins 
E3 proteins are best known for their immuno-modulatory functions (reviewed in Burgert et 
al., 2002; Horwitz 2004; Lichtenstein et al., 2004).  The E3-glycoprotein 19K (E3-gp19K) 
blocks MHC I transport to the plasma membrane, and thereby reduces the attack of 
infected cells by leukocytes.  E3-gp19K also lowers the cell surface levels of receptors for 
natural killer cells which furthers the survival of infected cells (Mcsharry et al., 2008).  E3-
14.7K (interference with apoptosis), E3-10.4K (named also receptor internalization and 
degradation RID-α), E3-14.5K (RID-β) and E3-6.7K block extrinsic apoptosis by down-
regulation of death receptors, and inhibition of cellular mediators that block the 
inflammatory and cell survival factor NF-κB.  In addition to apoptosis control, RID-α 
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induces a class III PI3-kinase-dependent cholesterol trafficking pathway that leads to the 
formation of autophagy-like vesicles distinct from late endosomal / lysosomal cholesterol 
storage compartments (Cianciola and Carlin 2009).  The observation that RID-α controls 
transport of low density lipoprotein-cholesterol complexes from endosomes to the ER for 
cholesterol esterification suggests that RID-α controls aspects of lipid droplet formation 
(Cianciola et al., 2013).  How these unexpected lipid trafficking phenotypes relate to cell 
death or innate immunity needs to be explored further.   
Recently, distinct features of an unusual E3 protein from HAdV-D19, E3-49K were 
reported (Windheim et al., 2013).  E3-49K is targeted to the secretory pathway and 
proteolytically cleaved to the soluble fragment E3-sec49K and released from infected 
cells.  E3-sec49K bound to leukocyte CD45, a receptor protein tyrosine phosphatase.  It 
reduced expression of activation markers on natural killer (NK) cells, and inhibited 
phosphorylation of T cell receptor, suggesting that it has immuno-modulating functions on 
natural killer (NK) cells and T cells, but the exact role of E3-sec49K in natural adenovirus 
infection is still unknown.    
E4 proteins 
The E4 region of HAdV-C encodes at least 7 distinct proteins involved in viral late gene 
expression, non-homologous end joining, DNA damage response, and apoptosis 
(reviewed in Weitzman 2005).  For example, E4orf6 together with E1B-55K from HAdV-C 
induces the selective export of viral late mRNAs from the nucleus to the cytoplasm, and 
inhibits export of cellular mRNAs (Flint and Gonzalez 2003).  Another E4 protein also 
cooperates with E1B-55K.  E4orf3 together with E1B-55K inhibits the MRN complex, 
which would otherwise block viral replication (see section E1B).   
Independent of this function, E4orf3 inhibits IFN production and disturbs the organization 
of promyelocytic leukemia protein (PML) bodies (also called PML oncogenic domain, or 
nuclear domain 10) (Carvalho et al., 1995; Ullman et al., 2007; Ullman and Hearing 2008; 
Leppard et al., 2009).  PML bodies are mounted by the IFN-induced proteins PML and 
Daxx, and they bind the HAdV E1A proteins depending on the CR2 region of E1A 
(Carvalho et al., 1995; Gongora et al., 2001).  Since the E4 locus is conserved across 
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many mastadenoviruses, including the human types, it is possible that E4orf3 acts to 
overcome species specific innate virus restriction.   
 
Domesticating HAdV - an outlook 
Coating the virus 
HAdV is the vector of choice for systemic gene delivery due to high stability and efficacy.  
Nonetheless, HAdVs bind to components of the blood, including erythrocytes, platelets, 
complement and coagulation factors, the viruses are sequestered to the liver, taken up 
into immune cells, destroyed by complement or trapped by non-target cells (Jiang et al., 
2004; Lyons et al., 2006; Othman et al., 2007; Stone et al., 2007; Carlisle et al., 2009b).  
For a schematic representation, see Fig. 3.  
To improve the pharmacokinetics of the virus, different strategies for virus surface 
modifications have been tested.  For example, HAdV-C2 has been coated with soluble 
fusion protein comprising the extracellular domain of CAR and the constant region of 
human Ig to target immune cells (Meier et al., 2005).  Alternatively, polymers are used to 
shield immunogenic proteins, such as hexon.  For example, coating the surface of HAdV 
with polyethylene glycol (PEG) is a well-studied modification (for example, Hofherr et al., 
2008; Green et al., 2012).  PEG-coated HAdVs elicit less intense immune responses 
compared to uncoated virus (O'riordan et al., 1999; Croyle et al., 2001).  Circulating 
proinflammatory cytokines, such as IL6, IL12 or TNFα, and liver transduction were 
reduced in primates receiving PEG-ylated compared to non-PEG-ylated HAdV 
(Wonganan et al., 2011).  Additionally, PEG-ylated HAdV can be functionalized by 
conjugation of antibodies, and this may increase the targeting of the vector to particular 
cell types (Kim et al., 2011).  Interestingly, PEG-ylation of HAdV-C_dE1/E3/E4 in 
combination with the anti-inflammatory glucocorticoid methylprednisolone reduced vector 
uptake into the spleen and non-parenchymal liver cells, and inhibited thrombocytopenia 
(De Geest et al., 2005).  This suggests that vector shielding and down-tuning of innate 
immunity is beneficial for vector applications in murine models.  
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Besides PEG, other polymers such as N-(2-hydroxypropyl)methacrylamide (HPMA) and 
chitosan have been successfully tested in preclinical studies (Carlisle et al., 2013; Kwon 
et al., 2013).  The combination of HPMA-coated HAdV with ultrasound gave increased 
vector delivery to tumors, while reducing liver toxicity compared to naked HAdV in 
immune deficient mice.   
Genetic alterations of the viral capsid 
Any surface modification of the vector exclusively affects the first round of infection, but 
not subsequent rounds of replication.  To shield progeny viruses, genetically modified 
vectors are used.  A common strategy has been to swap fibers between immunogenic 
and non-immunogenic HAdV types, or exchange immuno-dominant epitopes on the 
hexon protein.  For example, the fiber of the CAR-tropic HAdV-C5 has been transferred 
to the capsid core of HAdV-B35, which has one of the lowest levels of seroprevalence 
(Vogels et al., 2003).  Nonetheless, the fiber knob swapped HAdV-B35_FK5 was more 
immunogenic than HAdV-B35 in both non-human primates and mice (Nanda et al., 
2005), suggesting that either the knob of HAdV-C5 or the entry pathway of the CAR-
tropic HAdV-B35_FK5 was more immunogenic than the knob or the CD46 pathway of 
HAdV-B35 (Fleischli et al., 2005).  Clearly, further studies are needed to sort out the 
mechanisms of immune activation by HAdV in animals and humans.  
 
Conclusions 
In this review, we have laid out how HAdV is detected by the host innate immune system, 
and highlighted some of the mechanisms, by which the virus antagonizes innate 
responses.  It is clear that HAdV infection affects cell physiology in many ways, including 
transcriptional profiles and proteomes, and likely also metabolomes and lipidomes.  
HAdV also breaks the rules of membrane traffic by disrupting organelles, such as 
endosomes or the nuclear pore complex.  It is not unreasonable to expect that further 
danger signals from HAdVs will be discovered in studies with isolated cells or model 
animals, such as mice.  It should be noted, however, that mouse models have limitations 
for HAdV infection biology, as mice do not allow HAdV replication, unlike pigs, for 
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example (Jogler et al., 2006).  Alternative systems may overcome some of these 
limitations.  For example, human tissue explants with cell type complexities akin to 
human organs may allow to probe the impact of innate immune factors on HAdV 
replication and progeny production at single cell resolution in a complex cellular 
environment.  
Future studies will also deal the contested issue of multiplicity of infection (MOI).  
Researchers frequently use different MOI for cell and animal studies or between different 
cell types.  It is important to note here that both high and low MOI occur in lytic HAdV 
infections, and that viremia indicating high viral load is found in patients (Heemskerk et 
al., 2005; Yakimovich et al., 2012).  It is fundamentally important to define not only the 
number of viruses added to cells or animals, but also how many viruses actually bind and 
internalize to cells of interest and hence trigger infection or innate immune reactions.  For 
instance, high MOI may exacerbate particular innate immune responses by saturating 
limiting host functions that support infection, such as the nuclear pore complex for import 
of HAdV genomes into the nucleus (Wang et al., 2013).  This may enhance the innate 
response to danger signals, for example cytosolic viral DNA.  Finally, to address 
organismic mechanisms of adenoviruses innate immunity, we believe it is worth 
considering mouse adenoviruses (MAdVs).  For example, MAdVs elicit proinflammatory 
responses in murine airways similar to HAdV, despite considerable genetic differences 
between MAdV and HAdV (Meissner et al., 1997; Weinberg et al., 2005; Hemmi et al., 
2011). 
 
Outlook 
The recent development of methods to study the trafficking of viruses and subviral 
structures in both immune and non-immune cells now enables the field to further probe 
the mechanisms underlying the cell and immune biology of innate responses against 
HAdV.  From such experiments, an increased number of approaches using immuno-
stimulatory or immuno-reducing treatments for vector applications may emerge.  
Particular attention will be paid on careful dosing of the virus in order to control innate 
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immune reactions from the host, and to minimize unwanted inflammatory responses to 
the vector.  We also expect that major efforts will be spent on pushing the best 
understood HAdV-C vectors into clinical trials before other HAdV types with unknown 
features will be used in humans, although vaccinations with non-human adenoviruses are 
considered to be promising (Ewer et al., 2013).  In summary, a balanced mix of in vitro 
and in vivo studies complemented with clinical data will be essential to tackle the 
fundamental questions in innate immunity to HAdV.  Such approaches will also address 
other outstanding questions related to innate immunity, for example, how genetically 
identical cells and organisms can be variably susceptible to virus infections.   
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Legends to figures 
Figure 1: Schematic illustration of HAdV and key steps in HAdV entry 
 
A) Schematic cross-section of a prototypical HAdV with the most prominent structural 
features.  
B) Key entry features of HAdV entry into a generic cell, in relation to pathogen associated 
molecular patterns.  For details, see main text.  
 
 
Figure 2: Adenovirus-induced host innate responses  
 
The most prominent cellular innate signaling pathways elicited during HAdV entry 
comprise lectin receptors (LRs), toll-like receptors (TLRs), inflammasome signaling 
comprising AIM2-like receptors (ALRs), NOD-like receptors (NLRs) and RIG-I-like 
receptors (RLRs), autophagy and interferon (IFN) signaling.  In addition, defensins, 
intracellular antibodies and most importantly DNA sensors cGAS and DDX41 together 
with the adapter STING provide crucial innate defense against HAdV.  The virus 
antagonizes innate defense by early proteins of the E1, E3, and E4 regions, as well as by 
VA-RNAs.   
 
 
Figure 3: Domesticating adenovirus for gene therapy 
 
To tailor HAdV for clinical purposes, the capsid (left section, grey spheres) or genome 
(right section, grey spheres) can be modified.  Capsid modifications include swaps of 
fiber or fiber knob between different HAdV types, hexon modifications, or coating the 
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virus with chemicals, such as synthetic polymers.  Genome modifications involve deletion 
or replacement of viral genes or promoters to enhance or attenuate viral replication or 
toxicity.  The latter is prominently used in oncolytic approaches (lower section, black 
sphere) aiming to eliminate diseased tissue.  For details, see main text.  
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